Antiepileptic Drugs and Bone Loss: A Quiet Long-Term Risk
Of the long-term medication classes that affect bone, antiepileptic drugs (AEDs) are among the most consistently documented. Most large epilepsy cohorts show 2-3 fold increased fracture risk in long-term AED users, with effects emerging within 5-10 years of starting therapy. The fracture risk has both bone-density and seizure-related components. Understanding which drugs are involved and how to monitor matters for anyone on AEDs for epilepsy, mood stabilization, neuropathic pain, or migraine prophylaxis.
Which AEDs affect bone most
The classic enzyme-inducing AEDs — phenytoin, phenobarbital, carbamazepine, primidone — produce the largest bone-density effects. They induce hepatic enzymes that accelerate vitamin D metabolism, lowering serum 25-hydroxyvitamin D over time. Valproate has a different mechanism but produces similar bone loss in long-term use. Newer AEDs (lamotrigine, levetiracetam, topiramate, gabapentin, pregabalin) appear bone-neutral or close to it in most studies.
The vitamin D pathway
Enzyme-inducing AEDs accelerate the conversion of 25-hydroxyvitamin D to inactive metabolites. Without intervention, serum 25-hydroxy D often drops to deficient ranges within 2-3 years of starting therapy. The functional vitamin D deficit then drives secondary changes: lower calcium absorption, mild secondary hyperparathyroidism, and accelerated bone turnover.
What monitoring looks like
For long-term AED users, particularly on enzyme-inducing drugs: serum 25-hydroxyvitamin D annually, with a target of 35-50 ng/mL. DEXA at 5-year intervals starting at age 50 (or earlier if on AEDs for many years). Bone turnover markers (CTX, P1NP) can be used to assess response to interventions. Calcium intake and BMI tracking complete the picture.
Supplementation strategy
Most AED users on enzyme-inducing drugs need substantially higher vitamin D doses than typical adults — often 2000-4000 IU daily of D3, sometimes higher with retesting. Calcium intake should reach 1000-1200 mg per day, food-preferred. The supplementation requirement is dose-dependent on the AED used; valproate users sometimes need less aggressive supplementation than carbamazepine users.
When AED switch is considered for bone
Switching from an enzyme-inducing AED to a non-inducing one (when seizure control allows) can reverse some of the bone effect over years. This is a neurology decision, not a primary care one. The first priority is seizure control; bone considerations come second but inform long-term planning.
The seizure-fracture component
A significant portion of the elevated fracture rate in AED users comes from seizures themselves, particularly tonic-clonic seizures. Fall prevention, home safety modifications, and seizure control optimization all reduce fracture risk independently of bone density. This is why fracture risk in well-controlled epilepsy is much lower than in poorly-controlled epilepsy at the same BMD.
Frequently asked questions
Should I stop my AED for my bones?
No. Untreated seizures are far more dangerous than the AED bone effect. The discussion to have with your neurologist is monitoring and possibly switching drug class when seizure control allows.
How much vitamin D do AED users need?
Often 2000-4000 IU per day of D3, sometimes higher. The right dose is found by testing — aim for serum 25-hydroxy D of 35-50 ng/mL. Do not exceed 4000 IU without medical supervision.
Does the bone effect happen quickly?
BMD changes become measurable within 2-3 years for enzyme-inducing AEDs at usual doses. The fracture risk emerges over 5-10 years. Earlier intervention slows the trajectory.
Are AEDs used for non-epilepsy reasons (mood, pain) just as concerning?
In most studies, yes — the effect is drug-class-driven, not indication-driven. The newer non-inducing AEDs commonly used for mood or neuropathic pain (lamotrigine, pregabalin) are generally bone-friendlier.
Related reading: The Bone Density Solution review · Vitamin K2 and bone health
